CFAP95: A Potential Drug Target and Biomarker for Fibrosis and Chronic Pain

Target Name: CFAP95

NCBI ID: G138255

CFAP95

CFAP95: A Potential Drug Target and Biomarker for Fibrosis and Chronic Pain

Fibrosis and chronic pain are significant public health issues that affect millions of people worldwide. Fibrosis is a condition in which cells become stiff and mutate, leading to the loss of tissue function and quality of life. Chronic pain can be caused by various mechanisms, including inflammation, neural dysfunction, and cancer. The uncontrolled growth of fibroblasts, a type of cell that produces collagen, has been identified as a key factor in the development of fibrosis and chronic pain.

CFAP95, a protein produced by fibroblasts, has been identified as a potential drug target and biomarker for fibrosis and chronic pain. In this article, we will discuss the structure, function, and potential therapeutic applications of CFAP95.

Structure and Function of CFAP95

CFAP95 is a 95 amino acid protein that is expressed in high levels in fibroblasts. It is a member of the cytoskeletal protein family and is involved in the regulation of cell shape and movement. CFAP95 is primarily localized to the cytoskeleton and is not cytoplasmic. It has been shown to play a role in the regulation of cell division, cell migration, and cell-cell adhesion.

In addition to its cytoskeletal functions, CFAP95 has been shown to have various biological activities. It has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that regulates cell growth, differentiation, and inflammation. Studies have shown that CFAP95 can interact with and regulate the activity of TGF-β signaling pathway components, including Smad2, which is a key transcription factor that regulates the expression of genes involved in cell signaling and inflammation.

CFAP95 has also been shown to play a role in the regulation of cellular processes that are relevant to pain perception and fibrosis. Fibroblasts are involved in the production of extracellular matrix (ECM) components, including collagen, which is a key protein involved in the development of fibrosis. The production of ECM components by fibroblasts is regulated by various factors, including CFAP95. Studies have shown that CFAP95 can regulate the production of ECM components in response to various stimuli, including pain and inflammation.

Potential Therapeutic Applications of CFAP95

The potential therapeutic applications of CFAP95 are vast and varied. As a drug target, CFAP95 has the potential to treat a wide range of diseases that are characterized by the uncontrolled growth of fibroblasts and the production of ECM components.

One of the primary therapeutic applications of CFAP95 is the treatment of fibrosis. Fibrosis is a condition in which cells become stiff and mutate, leading to the loss of tissue function and quality of life. Fibrosis can be caused by various factors, including aging, chronic pain, and certain diseases, such as cancer. The uncontrolled growth of fibroblasts, as demonstrated by CFAP95, is a key factor in the development and progression of fibrosis.

CFAP95 has the potential to treat fibrosis by inhibiting the uncontrolled growth of fibroblasts and regulating the production of ECM components. This could be achieved through various mechanisms, including the inhibition of the activity of TGF-β, which is a key signaling pathway involved in fibrosis. By inhibiting TGF-β activity, CFAP95 could prevent the regulation of cellular processes that are involved in the production of ECM components, including collagen.

CFAP95 may also have potential therapeutic applications in the treatment of chronic pain. Chronic pain can be caused by various mechanisms, including inflammation, neural dysfunction, and cancer. The uncontrolled growth of fibroblasts, as

Protein Name: Cilia And Flagella Associated Protein 95

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "CFAP95 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP95 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets